الانتقال الى المحتويات

علم الأورام

معالجة فقر الدم

Erythropoiesis-Stimulating Agents

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (يفتح نافذة جديدة)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Source‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

مفهرسة‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (يفتح نافذة جديدة)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (يفتح نافذة جديدة)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Source‎: Acta Haematol 2007;117(3):162-7.

مفهرسة‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (يفتح نافذة جديدة)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (يفتح نافذة جديدة)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Source‎: Am J Hematol 2013;88(12):990-6.

مفهرسة‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (يفتح نافذة جديدة)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (يفتح نافذة جديدة)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Source‎: J Clin Oncol 2011;29(28):3791-7.

مفهرسة‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (يفتح نافذة جديدة)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (يفتح نافذة جديدة)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Source‎: Cancer 2012;118(3):848-55.

مفهرسة‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (يفتح نافذة جديدة)

Management of anemia in cancer patients. (يفتح نافذة جديدة)

Calabrich A, Katz A.

Source‎: Future Oncol 2011;7(4):507-17.

مفهرسة‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (يفتح نافذة جديدة)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (يفتح نافذة جديدة)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Source‎: BJU Int 2011;108(10):1582-7.

مفهرسة‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (يفتح نافذة جديدة)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (يفتح نافذة جديدة)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Source‎: J Clin Oncol 2010;28(13):2239-45.

مفهرسة‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (يفتح نافذة جديدة)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (يفتح نافذة جديدة)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Source‎: Br J Cancer 2011;105(9):1267-72.

مفهرسة‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (يفتح نافذة جديدة)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (يفتح نافذة جديدة)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Source‎: J Intern Med 2017;281(3):284-99.

مفهرسة‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (يفتح نافذة جديدة)

How I treat cancer-associated anemia. (يفتح نافذة جديدة)

Gilreath JA, Rodgers GM

Source‎: Blood 2020;136(7):801-13.

مفهرسة‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (يفتح نافذة جديدة)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (يفتح نافذة جديدة)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Source‎: Eur J Haematol. 2023 110(4):354-61.

مفهرسة‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (يفتح نافذة جديدة)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (يفتح نافذة جديدة)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Source‎: Cancer 2013;119(1):107-14.

مفهرسة‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (يفتح نافذة جديدة)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (يفتح نافذة جديدة)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Source‎: J Natl Cancer Inst 2013;105(14):1018-26.

مفهرسة‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (يفتح نافذة جديدة)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (يفتح نافذة جديدة)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Source‎: Support Care Cancer 2012;20(1):159-65.

مفهرسة‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (يفتح نافذة جديدة)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (يفتح نافذة جديدة)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Source‎: Leuk Lymphoma. 2019;60(9):2324-7.

مفهرسة‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (يفتح نافذة جديدة)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (يفتح نافذة جديدة)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Source‎: Oncologist 2010;15(9):935-43.

مفهرسة‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (يفتح نافذة جديدة)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (يفتح نافذة جديدة)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Source‎: Lung Cancer 2012;76(3):478-85.

مفهرسة‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (يفتح نافذة جديدة)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (يفتح نافذة جديدة)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Source‎: Eur J Haematol 2016;97(1):33-8.

مفهرسة‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (يفتح نافذة جديدة)

الحديد عن طريق الحقن ‏بالوريد

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (يفتح نافذة جديدة)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Source‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

مفهرسة‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (يفتح نافذة جديدة)

Intravenous iron in oncology. (يفتح نافذة جديدة)

Auerbach M, Ballard H.

Source‎: J Natl Compr Canc Netw 2008;6(6):585-92.

مفهرسة‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (يفتح نافذة جديدة)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (يفتح نافذة جديدة)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Source‎: Int J Colorectal Dis 2016;31(3):543-51.

مفهرسة‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (يفتح نافذة جديدة)

How I treat cancer-associated anemia. (يفتح نافذة جديدة)

Gilreath JA, Rodgers GM

Source‎: Blood 2020;136(7):801-13.

مفهرسة‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (يفتح نافذة جديدة)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (يفتح نافذة جديدة)

Gilreath JA, Stenehjem DD, Rodgers GM.

Source‎: J Natl Compr Canc Netw 2012;10(5):669-76.

مفهرسة‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (يفتح نافذة جديدة)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (يفتح نافذة جديدة)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Source‎: Eur J Haematol. 2023 110(4):354-61.

مفهرسة‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (يفتح نافذة جديدة)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (يفتح نافذة جديدة)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Source‎: Curr Oncol. 2023 24;30(9):7836-51.

مفهرسة‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (يفتح نافذة جديدة)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (يفتح نافذة جديدة)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Source‎: Cochrane Database Syst Rev 2016;(2):CD009624.

مفهرسة‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (يفتح نافذة جديدة)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (يفتح نافذة جديدة)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Source‎: World J Gastroenterol 2014;20(8):1972-85.

مفهرسة‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (يفتح نافذة جديدة)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (يفتح نافذة جديدة)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Source‎: South Asian J Cancer. 2023 15;12(2):93-9.

مفهرسة‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (يفتح نافذة جديدة)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (يفتح نافذة جديدة)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Source‎: J Clin Oncol 2008;26(10):1619-25.

مفهرسة‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (يفتح نافذة جديدة)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (يفتح نافذة جديدة)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Source‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

مفهرسة‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (يفتح نافذة جديدة)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (يفتح نافذة جديدة)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Source‎: Ann Oncol 2013;24(2):475-82.

مفهرسة‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (يفتح نافذة جديدة)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (يفتح نافذة جديدة)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Source‎: Am J Hematol 2024;99(7):1338-48.

مفهرسة‎: PubMed 38282557

DOI‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (يفتح نافذة جديدة)

علم الأورام
معالجة فقر الدم
العربية
معالجة فقر الدم
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

لجنة الاتصال بالمستشفيات (‏ل‌ام)‏

إتصل بأحد أفراد لجنة الاتصال بالمستشفيات المحلية التي تقدِّم لك المساعدة مجانًا.‏

اتصل بنا

رُزَم معلومات للأطباء

من جملة المواضيع:‏ تقنيات وإستراتيجيات لإيقاف النزف ومعالجة الأنيميا دون نقل دم،‏ موقف شهود يهوه الديني والأخلاقي من المعالجة الطبية،‏ والمساعدة التي يقدِّمونها للأطباء حول العالم عبر لجان الاتصال بالمستشفيات.‏

نزِّل المراجع

الفيديوات

تقترح هذه الفيديوات علاجات بديلة لنقل الدم.‏ وتلفت النظر الى المسائل الطبية والاخلاقية التي يلزم ان يأخذها الاطباء في الاعتبار حين يعالجون شهود يهوه.‏

شاهِد الفيديوات